Vasiliki Triantafyllia

Vasiliki Triantafyllia

Auto-generated profile, based on publicly available information

Vasiliki Triantafyllia

Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
NRNikoletta Rovina
Nikoletta Rovina
VLVicky Lampropoulou
Vicky Lampropoulou
VTVasiliki Triantafyllia
Vasiliki Triantafyllia
MMMaria Manioudaki
Maria Manioudaki
V0VAT Number: EL 090050626
VAT Number: EL 090050626

14 July 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ABA. Rouf Banday
A. Rouf Banday
MSMegan L. Stanifer
Megan L. Stanifer
OFOscar Florez-Vargas
Oscar Florez-Vargas
OOOlusegun O. Onabajo
Olusegun O. Onabajo
BPBrenen W. Papenberg
Brenen W. Papenberg
LPLudmila Prokunina-Olsson
Ludmila Prokunina-Olsson
The chr12q24.13 locus encoding OAS1–OAS3 antiviral proteins has been associated with coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and clinical insights into this locus in relation to COVID-19 severity. In our analysis of patients of European (n = 2,249) and African (n = 835) ancestries with hospitalized versus nonhospitalized COVID-19, the risk of hospitalized disease was associated with a common OAS1 haplotype, which was also associated with reduced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance in a clinical trial with pegIFN-λ1. Bioinformatic analyses and in vitro studies reveal the functional contribution of two associated OAS1 exonic variants comprising the risk haplotype. Derived human-specific alleles rs10774671-A and rs1131454-A decrease OAS1 protein abundance through allele-specific regulation of splicing and nonsense-mediated decay (NMD). We conclude that decreased OAS1 expression due to a common haplotype contributes to COVID-19 severity. Our results provide insight into molecular mechanisms through which early treatment with interferons could accelerate SARS-CoV-2 clearance and mitigate against severe COVID-19.

16 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
MPMario Andrés Pizzorno
Mario Andrés Pizzorno
LMLisa Miorin
Lisa Miorin
PBPaul Bastard
Paul Bastard
AGAdrian Gervais
Adrian Gervais
JCJean-Laurent Casanova
Jean-Laurent Casanova
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

17 January 2022 in Allergy
Verified
Journal Article
Closed access
PDF file
ETEfthymia Theofani
Efthymia Theofani
MSMaria Semitekolou
Maria Semitekolou
KSKonstantinos Samitas
Konstantinos Samitas
AMAnnie Mais
Annie Mais
IGIoanna E. Galani
Ioanna E. Galani
Georgina XanthouGeorgina Xanthou
Georgina Xanthou

3 February 2022 in STAR Protocols
Verified
Journal Article
Open access
IGIoanna-Evdokia Galani
Ioanna-Evdokia Galani
VTVasiliki Triantafyllia
Vasiliki Triantafyllia
EEEvridiki-Evangelia Eleminiadou
Evridiki-Evangelia Eleminiadou
V0VAT Number: EL 090050626
VAT Number: EL 090050626
Influenza A viruses (IAVs) are common respiratory viruses. Mouse models of IAV infection are valuable to study the mechanisms of IAV infection and pathology. Here, we present a detailed protocol for IAV infection of mice via intranasal administration. We detail the processing of mouse lung tissue and then describe the determination of viral load by several approaches including RNA, protein, or plaque-forming unit assays. This protocol may be adapted to other influenza strains or respiratory viruses.

8 February 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
AFAllan Feng
Allan Feng
EYEmily Y. Yang
Emily Y. Yang
AMAndrew Reese Moore
Andrew Reese Moore
SDShaurya Dhingra
Shaurya Dhingra
SCSarah Esther Chang
Sarah Esther Chang
PUPaul J. Utz
Paul J. Utz
The widespread presence of autoantibodies in acute infection with SARS-CoV-2 is increasingly recognized, but the prevalence of autoantibodies in non–SARS-CoV-2 infections and critical illness has not yet been reported. We profiled IgG autoantibodies in 267 patients from 5 independent cohorts with non–SARS-CoV-2 viral, bacterial, and noninfectious critical illness. Serum samples were screened using Luminex arrays that included 58 cytokines and 55 autoantigens, many of which are associated with connective tissue diseases (CTDs). Samples positive for anti-cytokine antibodies were tested for receptor blocking activity using cell-based functional assays. Anti-cytokine antibodies were identified in > 50% of patients across all 5 acutely ill cohorts. In critically ill patients, anti-cytokine antibodies were far more common in infected versus uninfected patients. In cell-based functional assays, 11 of 39 samples positive for select anti-cytokine antibodies displayed receptor blocking activity against surface receptors for Type I IFN, GM-CSF, and IL-6. Autoantibodies against CTD-associated autoantigens were also commonly observed, including newly detected antibodies that emerged in longitudinal samples. These findings demonstrate that anti-cytokine and autoantibodies are common across different viral and nonviral infections and range in severity of illness.